Section 2: Selection, Procurement and Distribution
2SPD-022
ON THE ROAD TO SERIALISATION: A PRATICAL APPLICATION
2SPD-021
NONCOMPLIANCE OF DATAMATRIX CODES, AN OBSTACLE TO IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE
2SPD-020
EXPIRED MEDICINES AND MEDICAL DEVICES, AN ACROBATIC MANAGEMENT
2SPD-019
EVALUATION OF THE INTRODUCTION OF A MEDICAL DEVICE FOR MECHANICAL INDUCTION OF LABOUR IN WOMEN WITH UNFAVOURABLE CERVIX
2SPD-018
AUDIT ON THE MANAGEMENT OF PERSONAL TREATMENT OF PATIENTS AT THE HOSPITAL
2SPD-017
ECHO-ENDOSCOPY : FOR A SOURCING AS SHARP AS A NEEDLE
2SPD-016
BIOSIMILARS OF INFLIXIMAB AND RITUXIMAB: DOES THE INITIAL STRATEGY OF SELECTION HELP THEIR PRESCRIPTIONS?
2SPD-015
RISK-ADAPTED MANAGEMENT OF DRUG SHORTAGES TO ENSURE PROPER CARE FOR PATIENTS IN MEDICAL NEED
2SPD-014
MULTIDISCIPLINARY STOCK MANAGEMENT AND REDUCED DISTRIBUTION OF MEDICINE UP TO A DRUG PATENT EXPIRY REDUCED EXPENSES WITHOUT COMPROMISING MEDICINE SUPPLY IN A HOSPITAL SETTING
2SPD-013
ECONOMIC IMPACT OF THE USE OF FLAT DOSE VS PERSONALISED DOSE OF PEMBROLIZUMAB
2SPD-012
RELATIVE VALUE UNITS AS A PRODUCTIVITY SCORE OF MANAGEMENT OF ONCOLOGY MEDICATION IN SPECIAL SITUATIONS
2SPD-011
NETWORK META-ANALYSIS OF FIRST-LINE ANTIANGIOGENIC DRUGS IN ADVANCED RENAL CELL CARCINOMA
2SPD-010
INDIRECT COMPARISON OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN LUNG CANCER
2SPD-009
ANALYSIS OF OLAPARIB AND TALAZOPARIB AS POSSIBLE THERAPEUTIC ALTERNATIVES IN ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION
2SPD-008
RISK ANALYSIS ON CYTOTOXIC CIRCUIT IN A CENTRAL PHARMACY
